Drug Profile

BR 55

Alternative Names: BR-55; BR55 CEUS; Perfluorobutane/nitrogen lipopeptide-coated microbubbles injection

Latest Information Update: 10 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bracco Diagnostics
Class Contrast media; Diagnostic agents
Mechanism of Action Image enhancers; Ultrasonography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Ovarian cancer; Pancreatic cancer
Phase I/II Solid tumours
Phase Unknown Crohn's disease

Most Recent Events

10 Feb 2025 Bracco Imaging plans a phase III trial for Crohns disease (Diagnosis)
06 Feb 2025 Investigation in Crohn's disease (Diagnosis) (IV)
06 Feb 2025 BR 55 receives Fast Track designation for Crohn's disease (Diagnosis) [IV,Injection] in Unknown

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com